Indeed, the standard of care for APL harboring the PML-RARA fusion is either all-trans-retinoic acid (ATRA) or arsenic trioxide, both of which lead to the degradation of the PML-RARA fusion protein61–65. Here, PML is linked to acute promyelocytic leukemia.